ReviewESC heart failure2017
The role of procalcitonin in acute heart failure patients.
Review in ESC heart failure, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Review
- Impact of recombinant human brain natriuretic peptide on emergency dialysis and prognosis in end-stage renal disease patients with type 4 cardiorenal syndrome.Scientific reports · 2023Article
- Infection as an under-recognized precipitant of acute heart failure: prognostic and therapeutic implications.Heart failure reviews · 2023Review
- New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy.International journal of molecular sciences · 2023Review
- Acute Bacterial Infections and Longitudinal Risk of Readmissions and Mortality in Patients Hospitalized with Heart Failure.Journal of clinical medicine · 2022Article
- Low-Level Elevations of Procalcitonin Are Associated with Increased Mortality in Acute Heart Failure Patients, Independent of Concomitant Infection.Life (Basel, Switzerland) · 2021Article
- Prognostic Role of Serum Procalcitonin Measurement in Adult Patients Admitted to the Emergency Department with Fever.Antibiotics (Basel, Switzerland) · 2021Article
- The difference in referencing in Web of Science, Scopus, and Google Scholar.ESC heart failure · 2019Article
- Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure.Heart and vessels · 2019Article
- Open access efforts begin to bloom: ESC Heart Failure gets full attention and first impact factor.ESC heart failure · 2019Review
- Irreversible oxidative post-translational modifications in heart disease.Expert review of proteomics · 2019Review
- Observational
- Acute Heart Failure Management.Korean circulation journal · 2018Review
- Early identification of acute heart failure at the time of presentation: do natriuretic peptides make the difference?ESC heart failure · 2018Article
- Biomarkers in Cardiorenal Syndromes.BioMed research international · 2018Review
- The role of procalcitonin in acute heart failure patients.ESC heart failure · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute dyspnoea is a common chief complaint in the emergency department and is mainly caused by cardiac and pulmonary underlying diagnoses. In patients with acute heart failure (AHF), an early initiation of adequate therapy is important to improve patient outcome. Clinical differentiation of pulmonary and cardiac underlying causes and of concomitant pathologies determines which therapeutic strategy is chosen. Procalcitonin is a marker of bacterial infection, which is markedly increased in AHF patients with concomitant bacterial infection and thus has the potential to guide the early initiation of adequate antibiotic therapy. The IMPACT-EU trial is a multicenter randomized controlled trial designed to test this hypothesis. This mini-review summarizes the current literature on procalcitonin in AHF and explains the design of the IMPACT-EU trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.